SOBI acquires Gamifant from Novimmune
Swedish Orphan Biovitrum AB (publ) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab (Gamifant) and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The acquisition means that the previously announced exclusive licence agreement with Novimmune will be superseded.
Through the acquisition of emapalumab, Sobi gains access to: All assets relating to emapalumab including intellectual property, patent rights, data and know-how. All relevant and highly experienced employees involved in the clinical and biopharmaceutical development of emapalumab. Options for the shared financial rights to NI-1701 and NI-1801, two product candidates in the field of immuno-oncology. A priority review voucher within the FDA priority review programme, offers companies investing in orphan drugs a cost reduction for the application fee for future products and shortens the review period. The voucher can be used or sold by Sobi.
The consideration for the acquisition is CHF 515 M (SEK 4,897 M), of which CHF 400 M was previously committed in the exclusive licence agreement for emapalumab. The acquisition is expected to be earnings neutral in 2019 and completed during Q3 2019, subject to customary closing conditions.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins